A Multi-Center, Single-Arm, Open-Label, Prospective, Phase 4 Study to Investigate the Safety and Efficacy of Rapidly Restarting Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Viremic and Virologically-Suppressed Male and Female HIV-Positive Patients Aged ≥18 Years Who Are Treatment-Experienced and Returning to Care After Experiencing a Treatment Interruption of ≥12 Weeks

Managing HIV well requires taking antiretroviral therapy (ART) every day, but many people living with HIV experience interruptions in their treatment. These pauses in medication can happen for many reasons, such as side effects, challenges with getting to the clinic, personal circumstances, stigma, or difficulties with everyday life. When HIV treatment is stopped, the viral load can increase, which may affect a person's health and make it easier for HIV to be passed on to others. Restarting treatment quickly after an interruption is important for both personal and public health. However, it can be difficult for people who miss doses to get back on treatment right away. There are often several steps and medical appointments required before restarting, such as waiting for lab results or reviewing medical history, which can cause further delays. These additional steps can make it even harder for people to re-engage and may discourage them from returning to care.
The REINITIATE study is designed for people living with HIV who have not taken any antiretroviral medications for at least the last 12 weeks. The study will offer participants a way to restart their HIV therapy quickly, by beginning treatment with B/F/TAF on the same day that they return to care. B/F/TAF is a widely used, once-daily HIV regimen, and is recommended in national treatment guidelines.
Researchers want to find out if this rapid restart approach is safe and effective, and whether it helps people regain control of HIV and remain in care. The study will also examine how many participants are able to keep the virus at a low level (viral suppression), stay engaged in their HIV care, and tolerate the medication after rapidly restarting treatment. In addition, the study will include interviews with some participants, to gain a better understanding of why they stopped taking their medications and what supported their return to treatment. These insights could help healthcare teams develop better ways to support people living with HIV in the future.

开始日期2026-03-23

申办/合作机构

Gilead Sciences, Inc.

[+1]

NCT07122557

/ Not yet recruitingN/AIIT

Real World Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide(BIC/FTC/TAF) in PLWH in Precarity Settings in France

In France, French citizens with an annual income less than 10339 euros are considered living with low-income and are eligible to benefit from a public universal healthcare insurance coverage called C2S (complémentaire santé solidaire). C2S covers primary care and hospital care. Non-citizens with low income, like some migrants, can also benefit from a public healthcare insurance coverage called AME ("Aide Medicale d'Etat" for State Medical Aid). These criteria are used as a marker of precarity settings (i.e., socio-economic vulnerability) in France. In France, HIV-related care and treatments are reimbursed at 100% (ALD30), whatever the level of precariousness. ART adherence has been shown significantly lower in PLWH with C2S health insurance coverage. Although BIC/FTC/TAF is a recommended preferred option in naive PLWH and in switch or maintenance therapy in most settings, due to the forgiveness profile and the high genetic barrier to resistance, boosted darunavir (DRV/r) remains even more widely used than 2nd generation InSTIs in populations in precarity settings, and Real World Effectiveness (RWE) with BIC/FTC/TAF is missing to better support its use in these settings.
Paris Bichat Hospital (located in one of the poorest districts in the Ile-de-France region) and Nantes university hospital (West France region) follow a cohort of PLWH with a high proportion of populations in precarity settings (i.e with C2S and AME health insurance coverage): Paris Bichat hospital: N=5143 PLWH (December 2021), sex ratio F/M 37/56%, Transgender Women 7%, and born in sub-Saharan African countries 49%. Nantes university hospital: N=2227 PLWH (December 2021), sex ratio F/M 35/65% and born in sub-Saharan African countries 33%. In this cohort of 7370 PLWH in both sites 50% are receiving an InSTI-based ART regimen, regardless of prior treatment history, and at least 40% are receiving care through the C2S or AME, respectively.

开始日期2025-09-01

申办/合作机构-

NCT07055451

/ Recruiting临床1期

A Phase 1b Study to Evaluate the Safety and Pharmacokinetics of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Neonates Exposed to HIV-1

The goal of this clinical study is to learn more about the study drug, Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), safety, tolerability, and pharmacokinetics (how B/F/TAF is absorbed, modified, distributed, and removed from the body of the participants) in neonates exposed to human immunodeficiency virus type 1 (HIV-1).
The primary objective of this study is to evaluate the safety and plasma pharmacokinetics (PK) (how B/F/TAF is absorbed, modified, distributed, and removed from the body of the participants) of B/F/TAF tablet for oral suspension (TOS) in full-term neonates exposed to HIV-1 but uninfected.

开始日期2025-08-12

申办/合作机构

Gilead Sciences, Inc.

100 项与富马酸丙酚替诺福韦/恩曲他滨/比克替拉韦相关的临床结果

登录后查看更多信息

100 项与富马酸丙酚替诺福韦/恩曲他滨/比克替拉韦相关的转化医学

登录后查看更多信息

100 项与富马酸丙酚替诺福韦/恩曲他滨/比克替拉韦相关的专利（医药）

登录后查看更多信息

143

项与富马酸丙酚替诺福韦/恩曲他滨/比克替拉韦相关的文献（医药）

2026-02-02·JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomes

Article

作者: Shallvari, Adrian ; Gennari, William ; Mussini, Cristina ; Zazzi, Maurizio ; Conti, Federico ; Corsini, Dario ; Rusconi, Stefano ; Albini, Laura ; Pontali, Emanuele ; Cozzi-Lepri, Alessandro ; Pezzati, Laura ; Volpe, Anna ; Rossetti, Barbara ; Vicenti, Ilaria ; Saracino, Annalisa ; Bruzzone, Bianca ; Forcina, Gabriele

Abstract:

Objectives:

To estimate the prevalence of NRTI and integrase strand transfer inhibitor (INSTI), drug resistance mutations (DRMs) in antiretroviral therapy (ART)-experienced people with HIV-1 (PWH) switched to bictegravir/emtricitabine/tenofovir alafenamide fumarate (B/F/TAF) and among those with HIV-RNA ≤50 copies/mL to assess the association with risk of viral rebound (VR).

Methods:

Data from the ARCA cohort were used to estimate resistance prevalence assuming a binomial distribution; 95% confidence intervals (CIs) were reported. Standard survival analysis with time-fixed covariate measured at B/F/TAF initiation was used to evaluate the association between detected resistance and risk of confirmed VR >50 copies/mL (2 consecutive values).

Findings:

We included 1414 PWH (973—69%—in the VR analysis). Overall, 27% were female, median age was 53 years (IQR 44–59). Major NRTI-DRMs were detected in 25% (95% CI: 22.5, 27.1). Major INSTI-DRMs affecting bictegravir were rare (0.6%, 95% CI: 0.2, 1.4). The overall rate of VR by 36 months was 5.3% (95% CI: 3.7–6.9%), confirming that viral rebound on B/F/TAF is a rare event. After controlling for confounding, NRTI resistance was not associated with VR, whereas a history of INSTI virological failure (VF) and major INSTI-DRMs were associated with VR (aRH 2.68, 95% CI: 1.40, 5.12; and aRH 4.21, 95% CI: 1.18, 15.02, respectively).

Conclusions:

In our cohort of PWH who were switched to B/F/TAF, NRTI-DRMs were common, but B/F/TAF remained effective in maintaining viral suppression despite their presence. However, previous failure to INSTI-based regimens and major INSTI-DRMs were risk factors for VR.

2026-02-01·DRUGS & AGING

Real-World Persistence After Starting Bictegravir- or Dolutegravir-Based Regimens Among Adults Aged ≥50 Years with HIV in the United States

Article

作者: Joseph, Daisha ; Menezes, Neia Prata ; McMahon, Peter ; Kong, Amanda M ; Christoph, Mary J ; Mordi, Uche ; Lucia, Jacqueline ; Yucuma, Daniela ; Askin, Gulce ; Lim, Travis

BACKGROUND:

Persistence and adherence to antiretroviral therapy (ART) are crucial for effective viral suppression and may be impacted by comorbidities and polypharmacy in older people with HIV (PWH). This study compared ART persistence among treatment-naive and treatment-experienced PWH aged ≥50 years who received bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG)-based regimens.

METHODS:

This observational, retrospective study utilized US medical and pharmacy claims data from HealthVerity Marketplace (1 January 2015 to 29 February 2024). PWH were aged ≥50 years and received B/F/TAF, dolutegravir/lamivudine (DTG/3TC), dolutegravir/abacavir/lamivudine (DTG/ABC/3TC), or DTG-based multitablet regimens (MTRs). Baseline characteristics were balanced using inverse probability of treatment weighting. Time to nonpersistence (i.e., discontinuation or switching) was depicted using Kaplan-Meier plots. Risk of nonpersistence was modeled using weighted Cox proportional hazards models.

RESULTS:

Overall, 32,448 PWH aged ≥50 years were included in the analysis; 77% were treatment experienced. Among treatment-experienced PWH, those who received B/F/TAF had significantly lower adherence during the baseline period than those who received DTG/3TC and significantly higher adherence during the baseline period than those who received DTG/ABC/3TC and DTG-based MTRs. Nonetheless, persistence on B/F/TAF was longer than DTG/ABC/3TC and DTG-based MTRs in both subgroups. Treatment-naive and treatment-experienced PWH who received B/F/TAF had significantly lower hazards of nonpersistence versus those who received DTG/ABC/3TC and DTG-based MTRs (all p < 0.001), as did treatment-naive PWH who received B/F/TAF versus DTG/3TC (p = 0.031).

CONCLUSIONS:

B/F/TAF was associated with higher persistence than other ART regimens among older PWH. Findings underscore the importance of tailored ART selection to address the unique challenges faced by older PWH.

2026-02-01·INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Efficacy of same-day initiation of antiretroviral therapy with coformulated bictegravir, emtricitabine, and tenofovir alafenamide: Week 48 results of a single-arm, open-label, multicenter clinical trial

Article

作者: Lu, Po-Liang ; Tang, Hung-Jen ; Sun, Hsin-Yun ; Liou, Bo-Huang ; Hung, Chien-Ching ; Huang, Yi-Chia ; Huang, Sung-Hsi ; Yang, Chia-Jui ; Cheng, Shu-Hsing ; Lin, Shih-Ping ; Lee, Yuan-Ti ; Ko, Wen-Chien

OBJECTIVES:

In a national program of integration of rapid HIV diagnosis with linkage to antiretroviral therapy (ART), this multicenter, single-arm trial evaluated the efficacy and feasibility of same-day initiation of coformulated bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) in a high-income setting.

METHODS:

Adults aged ≥20 years and without prior ART exposure were enrolled and started BIC/FTC/TAF within 24 hours of confirmed HIV diagnosis. Primary endpoints included engagement in care and plasma HIV RNA load (PVL) <50 copies/mL at Week 48. Secondary endpoints included PVL <200 copies/mL at Weeks 1, 4, and 48, and drug-related adverse events.

RESULTS:

Among 225 enrolled participants (94.2% being gay, bisexual, and other men who have sex with men), 34.9% had CD4 <200 cells/μL and 63.2% PVL >100,000 copies/mL. At Week 48, 96.0% of the participants retained in care, and 76.0% and 81.0% achieved PVL <50 copies/mL in intention-to-treat and per-protocol analysis, respectively; and 96.5% achieved PVL <200 copies/mL in per-protocol analysis. A high baseline PVL and low CD4 count were associated with lower odds of achieving PVL <50 copies/mL. No serious adverse events were attributable to BIC/FTC/TAF.

CONCLUSION:

Initiation of BIC/FTC/TAF on the same day of HIV diagnosis is feasible, safe, and efficacious in achieving virologic suppression and engagement in care.

545

项与富马酸丙酚替诺福韦/恩曲他滨/比克替拉韦相关的新闻（医药）

2026-04-02

·Firstwordpharma

Gilead ends HIV treatment study paused by the FDA

Nearly a year after a safety signal prompted the FDA to pause five HIV studies run by Gilead Sciences, the biopharma has terminated one affected programme: the Phase II/III WONDERS-2 trial. The study had been assessing a once-weekly oral regimen comprising GS-1720, an integrase strand transfer inhibitor, and GS-4182, a prodrug of capsid inhibitor lenacapavir, approved as Yeztugo as an HIV preventative and marketed as Sunlenca to treat multi-drug-resistant HIV.WONDERS-2 was comparing the combo against Gilead's megablockbuster HIV drug Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) in treatment-naive HIV patients, while a similar study, WONDERS-1, is testing the duo in patients who are virologically suppressed (see – Vital Signs: Gilead's fastest growing drugs and Vital Signs: Best selling drugs of 2025).According to ClinicalTrials.gov, while WONDERS-2 has ended, WONDERS-1 remains active. The FDA had placed a clinical hold on both trials in June after a subset of patients who received GS-1720 and GS-4182 experienced decreases in CD4-positive T-cell and absolute lymphocyte counts, which could indicate weakened immune systems. Three other Phase I studies evaluating the experimental HIV treatments alone, or in combination with each other, were also paused. "Following consultation with the FDA, Gilead has discontinued safety follow up in GS US 695 7156 (WONDERS-2), effectively terminating the study," a Gilead spokesperson told FirstWord. "All participants currently enrolled have CD4 and absolute lymphocyte count levels that have returned to baseline or are within normal ranges."Despite the setback, Gilead's late-stage HIV pipeline has other shots on goal. The biopharma is running the Phase III ARTISTRY-1 and ARTISTRY-2 trials, which are testing whether virologically suppressed patients can be switched to a fixed-dose tablet of bictegravir and lenacapavir without losing viral control. The former study enrolled close to 700 patients who were taking up to 11 daily antiretroviral pills, and the latter recruited nearly 600 patients on Biktarvy.

临床3期临床2期临床1期临床结果

2026-04-02

·集思广JSG咨询

402药讯华道生物推出 20 余万元CAR-T细胞疗法士泽生物完成五亿元C/C+轮融资

正大天晴TO-B3234罕见病II期临床首例入组中国生物制药核心企业正大天晴宣布，1类新药TQ-B3234胶囊（MEK1/2抑制剂）Ⅲ期临床试验在上海交通大学医学院附属第九人民医院完成首例患者入组。此前，TQ-B3234已被国家药品监督管理局药品审评中心纳入突破性治疗品种，用于神经纤维瘤病I型（NF1）相关的成人丛状神经纤维瘤（PN）的治疗。必贝特中国正式启动一项针对三阴性乳腺癌的II/III期临床试验 2026年4月1日，必贝特公司BEBT-209（CDK4/CDK6抑制剂）在中国正式启动一项针对三阴性乳腺癌的II/III期临床试验（试验编号：CTR20261149）。本研究为一项随机、对照、开放标签、多中心的IIb/III期临床研究，旨在评估BEBT-209联合卡铂和吉西他滨，与卡铂联合吉西他滨相比，用于治疗局部晚期或转移性三阴性乳腺癌的疗效和安全性。试验的目标入组人群包括：激素受体阴性、HER2阴性、三阴乳腺癌患者，疾病状态为局部晚期或晚期，需接受二线、三线及以上治疗，且病灶为不可切除。试验在中国境内开展，计划招募446例患者。本临床试验分为两组：试验组接受BEBT-209联合吉西他滨和卡铂治疗；对照组接受吉西他滨联合卡铂治疗。主要研究终点包括总生存期（OS）和客观缓解率（ORR）。博锐生物启动一项针对痛风及高尿酸血症患者的中国II期临床试验 2026年4月1日，博锐生物的SAP-001（GLUT9抑制剂）正式启动一项针对痛风及高尿酸血症患者的中国II期临床试验，试验编号为CTR20261050。该研究为多中心、随机、双盲、以非布司他为对照的II期临床试验，全称为“在原发性痛风伴高尿酸血症患者中评价BR2251片有效性和安全性的多中心、随机、双盲、非布司他对照的II期临床研究”。本次试验将在中国进行，计划入组受试者共160例。本研究的试验组药物为SAP-001，对照组药物为非布司他。该临床试验的主要终点为治疗12周时，不同时间点受试者血清尿酸（sUA）水平达标率的百分比，用以评价SAP-001的有效性和安全性。荃信生物慢性阻塞性肺病（COPD）的中国II期临床试验 2026年4月1日，荃信生物启动了QX008N（TSLP单克隆抗体）用于慢性阻塞性肺病（COPD）的中国II期临床试验（试验登记号：CTR20261238）。该研究是一项随机、双盲、安慰剂对照的探索性临床研究，旨在评估皮下注射JKN2401注射液在中、重度COPD患者中的疗效、炎症生物标志物特征及安全性。试验将在中国境内开展，计划目标入组人数为120例。试验组接受研究药物QX008N治疗。本研究的主要终点为24周治疗期间中、重度急性加重型COPD（AECOPD）的年化发生率。礼来又来一个，口服小分子GLP-1受体激动剂获批上市当地时间4月1日，礼来公司宣布，美国食品药品监督管理局(FDA)批准了礼来公司的口服小分子药物FoundayoTM(通用名:orforglipron)上市，用于治疗成人肥胖或伴有体重相关并发症的超重患者。该药物是全球首个获批的口服、小分子、非肽类GLP-1受体激动剂(GLP-1 RA)，标志着体重管理领域的一个重要里程碑。与目前主流的注射型GLP-1药物相比，FoundayoIM的最大优势在于其便捷性。吉利德终止HIV重磅试验 2026年4月1日，吉利德科学对外宣布，经与FDA沟通后，公司已正式终止旗下 HIV 在研药物联合疗法的2/3 期临床试验 Wonders-2 ，同时停止该试验的安全性随访工作。值得注意的是，此前 FDA 针对该款联合疗法相关试验下达的临床暂停令目前仍未解除，吉利德另一项同系列试验 Wonders-1 也依日处于暂停状态，这也意味着其下一代 IIV 每周囗服疗法的研发遭遇重要挫折。据悉，Wonders-1和 Wonders-2 均为吉利德布局的核心 2/3 期临床试验，两项试验均以公司已获批的经典HIV 药物必妥维(Biktarvy)为对照，测试整合酶链转移抑制剂 GS-1720 与衣壳抑制剂 GS-4182 的每周口服联合疗法的病毒抑制效果。诺和诺德放弃的药，KBP执意“复活” 2026年4月1日，据外媒获悉，在一笔13亿美元交易告吹并陷入欺诈指控后，新加坡生物科技公司KBP Biosciences正寻求从诺和诺德(Novo Nordisk)手中收回ocedurenone这款命运多舛的心脏病药物所有权。知情人士透露，尽管该药物在2024年II期临床失败，KBP仍组建专家团队重新评估ocedurenone的临床价值。鉴于双方正在纽约进行仲裁，这两件事都难度极大。通用细胞治疗帕金森病领军药企士泽生物完成五亿元C/C+轮融资，连续六年完成市场化融资此次融资将用于进一步支持士泽生物自主开发的多项“中国首发”或“全球首款”异体通用型iPSC衍生细胞新药推进至关键性确证临床阶段，提升公司“现货型”神经细胞新药的规模化、标准化生产能力及质量管理与控制体系，为士泽生物通用型细胞新药商业化应用的可及性提供保障。冲刺IPO+平价突破，华道生物推出 20 余万元CAR-T细胞疗法，改写抗癌药定价格局 2026年4月2日讯近日证监会网站披露信息显示，华道(上海)生物医药股份有限公司(下称“华道生物”)已向上海证监局提交首次公开发行股票并上市辅导备案报告，正式启动资本市场冲刺计划。生物医药行业持续创新，未来可期! 注:本文整理自行业公开信息，仅供参考！

临床2期细胞疗法ASH会议免疫疗法突破性疗法

2026-04-02

·Alien药说

吉利德终止HIV重磅试验

安全性“翻车”，CD4细胞不升反降，HIV长效疗法遭遇至暗时刻 4月1日，正值新一个季度的开端，全球制药巨头吉利德科学（Gilead Sciences）却发布了一则令人意外的公告：公司已正式终止一项代号为 Wonders-2 的关键性2/3期临床试验。这一决定并非公司主动的战略收缩，而是源于美国食品药品监督管理局（FDA）此前下达的临床暂停令至今未解，且试验中暴露出的安全性问题远比想象中严峻。这也意味着，吉利德寄予厚望的下一代每周口服一次的HIV疗法，遭遇了研发路上的重大挫折。一、试验终止：不仅是暂停，而是彻底停止根据吉利德发布的声明，此次被终止的Wonders-2试验是一项针对HIV在研药物联合疗法的2/3期临床研究。与“暂停”不同，“终止”意味着该试验将彻底结束，甚至连后续的安全性随访工作也已停止。这无疑是研发层面最坏的结果。通常只有当药物在疗效或安全性上完全失去前景时，药企才会做出如此决绝的决定。更令人担忧的是，此次危机具有连锁效应： Wonders-1试验：同样处于被FDA暂停的状态，至今未能重启。三项1期试验：涉及两款在研药物的单药或联合用药研究，也一并被纳入了FDA的临床暂停范围。二、致命信号：CD4细胞为何不升反降？这场危机的导火索，早在去年6月就已埋下。当时，FDA在常规的数据监测中发现，部分接受 GS-1720 与 GS-4182 联合用药的受试者，出现了一系列异常的血液学指标： CD4+T细胞水平降低总白细胞计数下降 CD4+T细胞是人体免疫系统中最重要的“指挥官”，也是衡量艾滋病患者免疫功能恢复的核心指标。对于任何一款抗HIV药物而言，其核心目标就是通过抑制病毒，让患者被破坏的CD4细胞数量恢复至正常水平。然而，在这项试验中，候选药物不仅没能有效保护这些细胞，反而导致了CD4细胞的减少。这种与治疗目标背道而驰的安全信号，直接触发了FDA最高级别的监管干预——临床暂停。三、重创：长效口服疗法的“降维打击” 吉利德在HIV领域拥有着统治级的地位，其“必妥维”等每日一次的单片方案是全球抗HIV治疗的“金标准”。近年来，吉利德致力于向更便捷的“长效疗法”进军，试图将服药频率从每日一次降低至每周一次，以减轻患者的服药负担，提高生活质量。此次受挫的GS-1720与GS-4182联合疗法，正是这一战略中的关键拼图。如果成功，它将成为首个每周口服一次的抗HIV方案。如今，这一核心项目的折戟，不仅意味着数亿美元的研发投入可能付诸东流，更让吉利德在长效口服技术路线上暂时失去了先发优势。竞争对手要么在长效注射剂上取得了进展，要么在更便捷的给药方式上持续发力，吉利德此次的“翻车”无疑给了对手追赶的机会。四、结语：安全永远是红线对于全球近4000万HIV感染者及高危人群来说，长效疗法依然是值得期待的未来。吉利德此次的教训再次印证了药物研发的铁律：在创新药的赛道上，安全永远是红线。即便是拥有丰富抗病毒经验的行业巨头，面对复杂的免疫系统，任何一个未预料到的靶点毒性，都足以让看似光明的研发管线瞬间崩塌。目前，吉利德尚未公布是否会彻底放弃这两款在研药物，还是寻求更低剂量或调整给药方案以解决CD4细胞减少的问题。但就目前来看，其每周一次口服方案的上市进程，已被迫按下了漫长的暂停键。本文基于公开信息整理，不构成任何投资或用药建议。

100 项与富马酸丙酚替诺福韦/恩曲他滨/比克替拉韦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J05AR	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
HIV感染	美国	Gilead Sciences, Inc.	2018-02-07

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
禁食	临床3期	美国	Merck Sharp & Dohme Corp.	2022-08-01
代谢综合征	临床3期	美国	Merck Sharp & Dohme Corp.	2022-08-01
肥胖	临床3期	美国	Merck Sharp & Dohme Corp.	2022-08-01
乙型肝炎	临床3期	美国	Gilead Sciences, Inc.	2018-05-30
乙型肝炎	临床3期	中国	Gilead Sciences, Inc.	2018-05-30
乙型肝炎	临床3期	日本	Gilead Sciences, Inc.	2018-05-30
乙型肝炎	临床3期	多米尼加共和国	Gilead Sciences, Inc.	2018-05-30
乙型肝炎	临床3期	法国	Gilead Sciences, Inc.	2018-05-30
乙型肝炎	临床3期	希腊	Gilead Sciences, Inc.	2018-05-30
乙型肝炎	临床3期	中国香港	Gilead Sciences, Inc.	2018-05-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06104306 (CTgov)	临床4期	HIV感染	33	B/F/TAF	衊衊齋壓蓋衊鹽糧觸蓋 = 廠遞範積餘艱積淵醖齋鹽窪願鹹網選壓壓築鬱 (鬱窪構繭夢鹹網獵壓簾, 願構願齋鑰襯鏇壓製鬱 ~ 遞艱艱鏇襯艱願糧簾簾) 更多	-	2026-02-11
NCT04734652 (INSIGHT, Pubmed \| Lancet HIV)	临床2期	HIV感染	122	Bictegravir-emtricitabine-tenofovir alafenamide	積繭醖憲簾窪糧鬱觸鏇(顧顧築網網鬱淵廠壓艱) = 鏇襯醖範鹽範淵構願餘餘憲鹹鏇鏇淵觸築壓糧 (遞觸築淵構觸鹹製網網, 86 ~ 98) 更多	积极	2025-12-01
				Dolutegravir + tenofovir + lamivudine	積繭醖憲簾窪糧鬱觸鏇(顧顧築網網鬱淵廠壓艱) = 範壓築觸選膚範簾蓋顧餘憲鹹鏇鏇淵觸築壓糧 (遞觸築淵構觸鹹製網網, 84 ~ 99) 更多
NCT04712058 (Pubmed \| Int J Infect Dis)	临床3期	HIV感染	225	Bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF)	蓋鏇壓鹹構壓遞廠構願(廠網淵膚鏇網觸壓蓋膚) = 築衊衊夢糧顧廠簾齋廠獵鬱鹽鏇醖鹹觸衊艱願 (醖積遞網夢襯遞選齋製 ) 更多	积极	2025-12-01
NCT05122754 (Pubmed \| Infect Dis Ther)	临床3期	HIV感染	150	Bictegravir/Emtricitabine/Tenofovir Alafenamide	積獵鏇構膚蓋願繭廠網(夢襯膚選願鹽鹹獵鹽窪) = 齋餘夢糧鹽築積製夢範願鏇遞餘鏇簾鑰鹽觸遞 (艱齋糧觸築醖衊鹽鹽餘, 0.20 ~ 4.12) 更多	积极	2025-11-21
				Tenofovir Disoproxil Fumarate-Based Regimens	積獵鏇構膚蓋願繭廠網(夢襯膚選願鹽鹹獵鹽窪) = 構鬱鑰顧鑰鑰鹽鹽鬱壓願鏇遞餘鏇簾鑰鹽觸遞 (艱齋糧觸築醖衊鹽鹽餘, −0.52 ~ 3.15) 更多
NCT04734652 (INSIGHT study \| INSIGHT, CTgov)	临床2期	获得性免疫缺陷综合征 \| 肺结核	122	Biktarvy® (BIC Arm)	鑰鬱艱衊艱鬱襯構觸蓋 = 築壓觸遞憲壓網壓鹹醖淵鹽獵積艱製遞廠鏇糧 (選糧鬱鬱憲範醖廠網觸, 淵鹹顧範願艱鹹淵範窪 ~ 選顧憲範壓獵製製襯繭) 更多	-	2025-08-15
				Tenofovir+Dolutegravir+Lamivudine (DTG Arm)	鑰鬱艱衊艱鬱襯構觸蓋 = 淵廠製製構積蓋襯憲範淵鹽獵積艱製遞廠鏇糧 (選糧鬱鬱憲範醖廠網觸, 衊淵願鑰糧憲醖積選顧 ~ 艱觸淵醖築憲膚簾壓鑰) 更多
NCT03580668 (BICSTaR, BusinessWire) 人工标引	N/A	HIV感染	-	Biktarvy (treatment‐naïve)	範艱網糧鬱窪選構餘鹽(齋淵憲顧艱膚遞廠選構) = 膚網鹽積築廠衊顧齋網蓋築網製憲鹽鹹膚壓遞 (構壓鬱鹽憲鏇鹽蓋壓選 ) 更多	积极	2024-11-12
				Biktarvy (treatment‐experienced)	範艱網糧鬱窪選構餘鹽(齋淵憲顧艱膚遞廠選構) = 顧顧積廠衊夢醖獵網製蓋築網製憲鹽鹹膚壓遞 (構壓鬱鹽憲鏇鹽蓋壓選 ) 更多
NCT03547908 (ALLIANCE, BusinessWire) 人工标引	临床3期	乙型肝炎 \| HIV感染	-	Biktarvy	齋衊觸願構壓範壓艱壓(淵夢鏇構膚範鏇範築膚) = 繭鹽衊繭繭壓獵製餘築餘簾鬱鹽襯範鏇淵蓋衊 (積夢壓醖觸餘艱襯膚餘 ) 更多	积极	2024-11-12
NCT02607956 \| NCT02607930 (Study 1489; Study 1490, Pubmed \| Future Microbiol)	临床3期	HIV感染	-	Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)	齋齋蓋鬱繭網蓋觸膚齋(廠壓膚觸餘齋積衊淵製) = 餘醖製蓋製鏇獵鬱壓製選醖網醖壓艱遞獵鏇膚 (顧觸選鹽範獵製膚憲獵 ) 更多	积极	2024-09-04
NCT04416906 (Pubmed \| J Antimicrob Chemother) 人工标引	临床3期	HIV感染一线	100	Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)	觸齋築齋膚淵醖製範鑰(顧觸憲鹽願餘構願選壓) = 蓋築壓鏇廠壓廠鹹繭鏇製襯繭遞鹹製夢簾鏇窪 (觸蓋蓋鏇膚壓構廠蓋築 ) 更多	积极	2024-07-24
NCT02607956 \| NCT02607930 (Studies 1489 and 1490, Pubmed \| AIDS)	临床3期	HIV感染	519	Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)	壓構觸獵繭鹽鹹簾糧鹽(繭壓壓獵鹽網顧鹹鹹襯) = Two participants discontinued B/F/TAF due to treatment-related AEs 製簾遞壓獵蓋壓願獵製 (顧觸廠鏇艱鏇蓋製糧範 ) 更多	积极	2024-06-01
				Dolutegravir/F/TAF